AstraZeneca Pharma India is set to launch Eculizumab (Soliris) in August 2025, targeting the treatment of rare blood disorders PNH and aHUS. The drug inhibits complement-mediated thrombotic microangiopathy and received CDSCO approval earlier this year.
